AI-Powered Drug Discovery

AI-driven discoveryfor the medicinesof a precision-medicine era

Focused on the neural and vascular axes, combining an AI platform with nanomedicine to develop effective, safe, and precise next-generation therapies.

Explore our technology
01AiPLEX selection
02AiTOX toxicology
03ADMET assessment
04Candidate assessment
01FUTURE AI

A precision candidate-assessment platform built on toxicology

Future AI's core value lies not only in finding an effective drug, but in systematically identifying and removing high-risk candidates early in R&D. By embedding toxicology and safety assessment into AI-driven selection and decision-making, toxicology becomes a key determinant of candidate survival rather than a late-stage check.

01

Drug–disease matching

AiPLEX selection engine

Combines pharmacology, dosage-form assessment, and patent/clinical needs to precisely match drugs to indications across multiple disease areas.

Pharmacology · Dosage form · Patent/Clinical

02

Safety & toxicology prediction

AiTOX toxicology

Provides safety and ADMET assessment, aiming for animal-test-free toxicology prediction that screens out high-risk candidates early.

ADMET · DDI · Safety

03

Candidate optimization

Platforms in concert

AiPLEX and AiTOX work together to systematically screen and rank drug candidates, completing process development and in vitro / in vivo validation.

Candidates · Systematic · Ranking

04

Dementia lead application

Current focus

Has identified drug candidates that improve blood-brain-barrier penetration and promote neural repair, while advancing patent filing and toxicology-led preclinical validation.

BBB · Neural repair · Dementia

AiPLEX

AI selection engine

Finding the candidates worth pursuing, for every indication.

Selection engineMulti-indicationDementia
Learn more
02PIPELINE

Ten candidates targeting hard-to-treat diseases

The pipeline spans ten indications including erectile dysfunction, vascular dementia, pulmonary arterial hypertension, and Alzheimer's disease; lead product FPT-001 has obtained Phase II clinical approval in Australia.

Vascular Axis

6
FPT-001Phase II

Erectile dysfunction (ED)

PBF Pharma
FPT-002Preclinical

Benign prostatic hyperplasia (BPH)

MOU in progress
FPT-004Discovery

Pulmonary arterial hypertension (PAH)

FPT-006Discovery

Coronary artery disease (CAD)

FPT-008Discovery

Metabolic-associated steatohepatitis (MASH)

MOU in progress
FPT-010Discovery

Androgenetic Alopecia (AGA)

Neural Axis

4
FPT-003IND

Vascular Dementia

MOU in progress
FPT-005Discovery

Traumatic brain injury (TBI)

FPT-007Preclinical

Alzheimer's disease (AD)

FPT-009Preclinical

Myopia

In talks
Learn more
03ABOUT US

About the company

Redefining drug discovery with AI

Founded in 2021, Future PharmaTech focuses on the body's two great axes of life — neural and vascular — using an innovative AI drug-development platform and nanomedicine to accelerate discovery, complete trials faster, and create effective, safe, and precise therapies for hard-to-treat diseases such as vascular dementia (VaD) and erectile dysfunction (ED).

Guided by the principle of "not changing the patient's lifestyle," the company designs next-generation therapies that balance efficacy and comfort. Its core technology, the Future-AI platform, integrates drug repurposing and mechanism simulation to achieve precise delivery across the blood-brain barrier (BBB), raising efficacy while reducing side effects.

The team brings together senior experts in pharmaceutical R&D, AI, and business operations, and partners actively with leading research institutions and pharmaceutical companies — aiming to shorten the development cycle to within five years and deliver breakthrough therapies.

2

AI Platforms

10

Drug Candidates

10

Patent Regions

Learn more
04LATEST NEWS

Latest news

Future PharmaTech's FPT-001 obtains US FDA clinical trial authorization, advancing toward international validation

Media

Future PharmaTech's FPT-001 obtains US FDA clinical trial authorization, advancing toward international validation

FPT-001 has obtained an Investigational New Drug (IND) authorization from the US FDA and may begin Phase I/II human trials under the approved protocol — a further international regulatory advance after Australia. FPT-001 targets male erectile dysfunction through an optimization pathway built on a combination of already-approved ingredients, and pairs the AiTOX AI toxicology-prediction platform with the NVIDIA Nemotron LLM to rapidly assess drug safety and metabolic mechanism, accelerating its clinical and international licensing plans.

2026-08-14Source: Economic Daily
Future PharmaTech in Boston — focusing on AI toxicology and drug repurposing

Media

Future PharmaTech in Boston — focusing on AI toxicology and drug repurposing

In Boston, Future PharmaTech met with international investors and set out a technology roadmap centered on AI toxicology prediction (AI Toxicology) and drug repurposing, aligned with the global pharmaceutical industry's push to lower R&D costs and raise efficiency. External validation of the models and the quality of clinical data were the focus of attention during the exchange; the company will continue to treat solid clinical validation as the foundation for putting its technology into practice.

2026-07-06Source: GeneOnline Monthly
Future PharmaTech visits Monte Jade New England at MassBio in Boston, deepening Taiwan-US biotech links

Media

Future PharmaTech visits Monte Jade New England at MassBio in Boston, deepening Taiwan-US biotech links

On July 1 the Startup Island TAIWAN delegation visited the Monte Jade Science and Technology Association of New England at MassBio headquarters in Boston. Led by DCB Chairman Twu Shiing-Jer, nearly 30 Taiwanese and US biotech professionals gathered for the exchange. Future PharmaTech, one of the five Taiwanese startups on the trip, delivered a pitch presentation on site, raising the international visibility of Taiwan's biomedical startups and deepening Taiwan-US industry links.

2026-07-04Source: OCAC News
Learn more

GET IN TOUCH

Partnership, investment, or technology?

Contact us